Document is current
Any future updates will be listed below
-
Authors
Gausdal, Gro
Micklem, David R
Blø, Magnus
Rayford, Austin
Alzhanova, Dina
Madeleine, Noëlly
Taverna, Josephine Amalia
Hung, Chia-Nung
Brekken, Rolf A
Chisamore, Michael
Gorcea-Carson, Claudia
Oliva, Cristina
McCracken, Nigel
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03184571 at ClinicalTrials.govnct03184571 at ClinicalTrials.govDocuments that mention this clinical trial
602 AXL targeting with bemcentinb restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of TCF1+ CD8 T cells
https://doi.org/10.1136/jitc-2021-sitc2021.602
Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects
https://doi.org/10.1136/jitc-2022-004863
598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571)
https://doi.org/10.1136/jitc-2023-sitc2023.0598
nct03184571 at ClinicalTrials.govDocuments that mention this clinical trial
602 AXL targeting with bemcentinb restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of TCF1+ CD8 T cells
https://doi.org/10.1136/jitc-2021-sitc2021.602
Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects
https://doi.org/10.1136/jitc-2022-004863
598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571)
https://doi.org/10.1136/jitc-2023-sitc2023.0598
Documents that mention this clinical trial
602 AXL targeting with bemcentinb restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of TCF1+ CD8 T cells
https://doi.org/10.1136/jitc-2021-sitc2021.602
Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects
https://doi.org/10.1136/jitc-2022-004863
598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571)
https://doi.org/10.1136/jitc-2023-sitc2023.0598
- License Information
